Back to Journals » Drug Design, Development and Therapy » Volume 11

Functional assessment of CYP3A4 allelic variants on lidocaine metabolism in vitro

Authors Fang P, Tang P, Xu R, Zheng X, Wen J, Bao S, Cai J, Hu G

Received 22 September 2017

Accepted for publication 25 October 2017

Published 7 December 2017 Volume 2017:11 Pages 3503—3510

DOI https://doi.org/10.2147/DDDT.S152366

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr Tuo Deng


Ping Fang,1 Peng-fei Tang,1 Ren-ai Xu,2 Xiang Zheng,1 Jian Wen,1 Su-su Bao,1 Jian-ping Cai,3 Guo-xin Hu1

1Department of Pharmacology, School of Pharmacy, Wenzhou Medical University, 2Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 3The Ministry of Health (MOH) Key Laboratory of Geriatrics, Beijing Hospital, National Center of Gerontology, Beijing, China

Aim: Human cytochrome P450 3A4 is the most abundant isoform of P450 enzyme in the liver. It plays an important role in the metabolism of wide variety of xenobiotic and endogenous substrates. So far, there are few reports about the functional characterization of CYP3A4 variants in terms of specific substrates. The aim of this study was to systematically investigate the genetic polymorphisms of 23 CYP3A4 alleles and evaluate their catalytic activities on the metabolism of lidocaine in vitro.
Methods and results: The wild-type and 22 CYP3A4 variants were expressed in Spodoptera frugiperda 21 insect cells. Then the insect microsomes were incubated with the CYP3A4-specific substrate lidocaine. Reactions were performed with 50–3,000 µM for 60 min at 37°C. Lidocaine and its metabolite monoethylglycinexylidide were analyzed by ultra-performance liquid chromatography-tandem mass spectrometry system. Of the 23 CYP3A4 allelic variants tested, 2 variants (CYP3A4*17 and CYP3A4*30) had no detectable enzyme activity; and 5 variants (CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16 and CYP3A4*24) showed significantly decreased intrinsic clearance values compared with wild-type CYP3A4*1.
Conclusion: As the first study of all these CYP3A4 alleles for lidocaine metabolism, our results in vitro assessment may provide novel insights into the allele-specific and substrate-specific activity of CYP3A4 and may also offer a reference to the personalized treatment of lidocaine in a clinical setting.

Keywords: CYP3A4, genetic polymorphism, drug metabolism, lidocaine, personalized treatment
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]